GlaxoSmithKline To Develop Stevenage R&D Facility

Drugs giant GlaxoSmithKline plc (GSK,GSK.L) announced a new development plan that will create up to 5,000 new jobs over the next decade.

GSK said it has formally started the process to extend its existing 92-acre Research & Development site in Stevenage.

As part of the plan, GSK is planning to sell nearly a third of the site or 33 acres of land, with an aim to unlock up to £400 million in new investment from a private sector developer to build the new campus and potentially create up to 5,000 highly-skilled jobs, over the next five to ten years.

The company expects to select a development partner later this year, with a view for work to begin on master planning for the new campus in 2022.

Tony Wood, Senior Vice President, Medicinal Science & Technology, GSK said: "The past 18 months has shown the UK life sciences sector at its best and the UK has recently unveiled an ambitious 10-year vision for the UK life sciences sector. Our goal is for Stevenage to emerge as a top destination for medical and scientific research by the end of the decade. We are excited to find a development partner to realise our vision to foster the next generation of world-class scientists and biotechnology firms in Britain."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
This Black Friday and the following holiday season, retailers across the United States are urged to keep up their inventory amid expected surge in shopping as majority of Americans wait till last minute to fill their baskets, according to certain studies. A new Oracle Retail survey, which was conducted last week and presented earlier this week, showed that 66 percent of consumers were less than Eagle, Idaho -based Flagship Food Group is recalling certain TJ Farms Select brand frozen cauliflower, citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves a limited number of cases of TJ Farms Select cauliflower that comes in 16 oz. packages with lot code 2077890089 and UPC code 75544000604-3. The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals Co. Ltd.'s Livtencity (maribavir) as the first drug to treat post-transplant cytomegalovirus or CMV in adults and pediatric patients. The approval is to treat patients 12 years of age and older and weighing at least 35 kilograms with post-transplant CMV infection/disease that does not respond...
Follow RTT